(Health-NewsWire.Net, November 02, 2016 ) Report Summary
Breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-negative breast cancer market, with coverage of multiple settings; neoadjuvant, adjuvant, first-, second-, third-, and fourth-line metastatic.
Overall five year survival in breast cancer is relatively high, at around 90%, but this is subjective to the subtype and stage of the disease. Importantly this report segments HER2 negative breast cancer into its two major subtypes; hormone receptor positive (HR+) and triple negative breast cancer (TNBC).
Indeed, the new drugs that will be entering the market will command a premium price in multiple settings, and there will be a steady increase in the incident cases of the disease (1.8% AGR) over the forecast period. However, it should be noted that, compared with other countries in the 5EU, the market in Germany will grow at a slower rate, with its share of the global market ultimately decreasing from 9% in 2013 to 8% in 2023.
Request for Sample: http://www.reportsweb.com/inquiry&RW0001432415/sample
Report Scope
- Overview of HER2-Negative Breast Cancer including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in 5EU including product HER2-Negative Breast Cancercription, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in 5EU from 2013-2023. - Analysis of the impact of key events as well the drivers and restraints affecting the 5EU HER2-Negative Breast Cancer market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for HER2-Negative Breast Cancer. - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of drug performance - Obtain sales forecast for drugs from 2013-2023 in the 5EU.
Inquire for Discount: http://www.reportsweb.com/inquiry&RW0001432415/discount
About Us ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers.
Contact Us: Phone: +1-646-491-9876 Email: sales@reportsweb.com
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
|